Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 49

1.

Designable nanoplasmonic biomarkers for direct microscopy cytopathology diagnostics.

Wang L, Darviot C, Zapata-Farfan J, Patskovsky S, Trudel D, Meunier M.

J Biophotonics. 2019 Jul 31:e201900166. doi: 10.1002/jbio.201900166. [Epub ahead of print]

PMID:
31365187
2.

Nodular Regenerative Hyperplasia: Expression Pattern of Glutamine Synthetase and a Potential Role for Hepatic Progenitor Cells.

Guilbert MC, Therrien A, Soucy G, Trudel D, Nguyen BN.

Appl Immunohistochem Mol Morphol. 2019 Jul 18. doi: 10.1097/PAI.0000000000000793. [Epub ahead of print]

PMID:
31335486
3.

Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network.

Grosset AA, Ouellet V, Caron C, Fragoso G, Barrès V, Delvoye N, Latour M, Aprikian A, Bergeron A, Chevalier S, Fazli L, Fleshner N, Gleave M, Karakiewicz P, Lacombe L, Lattouf JB, van der Kwast T, Trudel D, Mes-Masson AM, Saad F; Canadian Prostate Cancer Biomarker Network.

PLoS Med. 2019 Jul 2;16(7):e1002847. doi: 10.1371/journal.pmed.1002847. eCollection 2019 Jul.

4.

Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer.

Furrer D, Grégoire J, Turcotte S, Plante M, Bachvarov D, Trudel D, Têtu B, Douville P, Bairati I.

PLoS One. 2019 Jun 20;14(6):e0218621. doi: 10.1371/journal.pone.0218621. eCollection 2019.

5.

WISP1 is associated to advanced disease, EMT and an inflamed tumor microenvironment in multiple solid tumors.

Gaudreau PO, Clairefond S, Class CA, Boulay PL, Chrobak P, Allard B, Azzi F, Pommey S, Do KA, Saad F, Trudel D, Young M, Stagg J.

Oncoimmunology. 2019 Mar 22;8(5):e1581545. doi: 10.1080/2162402X.2019.1581545. eCollection 2019.

PMID:
31069142
6.

Retrospective study on the benefit of adjuvant radiotherapy in men with intraductal carcinoma of prostate.

Trinh VQ, Benzerdjeb N, Chagnon-Monarque S, Dionne N, Delouya G, Kougioumoutzakis A, Sirois J, Albadine R, Latour M, Mes-Masson AM, Hovington H, Bergeron A, Zorn KC, Fradet Y, Saad F, Taussky D, Trudel D.

Radiat Oncol. 2019 Apr 25;14(1):60. doi: 10.1186/s13014-019-1267-3.

7.

Proteases and their inhibitors as prognostic factors for high-grade serous ovarian cancer.

Trudel D, Avarvarei LM, Orain M, Turcotte S, Plante M, Grégoire J, Kappelhoff R, Labbé DP, Bachvarov D, Têtu B, Overall CM, Bairati I.

Pathol Res Pract. 2019 Jun;215(6):152369. doi: 10.1016/j.prp.2019.02.019. Epub 2019 Mar 2.

PMID:
30987833
8.

Integration of a Raman spectroscopy system to a robotic-assisted surgical system for real-time tissue characterization during radical prostatectomy procedures.

Pinto M, Zorn KC, Tremblay JP, Desroches J, Dallaire F, Aubertin K, Marple E, Kent C, Leblond F, Trudel D, Lesage F.

J Biomed Opt. 2019 Feb;24(2):1-10. doi: 10.1117/1.JBO.24.2.025001.

PMID:
30767440
9.

Combining high wavenumber and fingerprint Raman spectroscopy for the detection of prostate cancer during radical prostatectomy.

Aubertin K, Desroches J, Jermyn M, Trinh VQ, Saad F, Trudel D, Leblond F.

Biomed Opt Express. 2018 Aug 15;9(9):4294-4305. doi: 10.1364/BOE.9.004294. eCollection 2018 Sep 1.

10.

Identification of the Transcription Factor Relationships Associated with Androgen Deprivation Therapy Response and Metastatic Progression in Prostate Cancer.

Sharma NV, Pellegrini KL, Ouellet V, Giuste FO, Ramalingam S, Watanabe K, Adam-Granger E, Fossouo L, You S, Freeman MR, Vertino P, Conneely K, Osunkoya AO, Trudel D, Mes-Masson AM, Petros JA, Saad F, Moreno CS.

Cancers (Basel). 2018 Oct 11;10(10). pii: E379. doi: 10.3390/cancers10100379.

11.

Correction to: HtrA1 expression and the prognosis of high-grade serous ovarian carcinoma: a cohort study using digital analysis.

Gagné A, Têtu B, Orain M, Turcotte S, Plante M, Grégoire J, Renaud MC, Bairati I, Trudel D.

Diagn Pathol. 2018 Sep 17;13(1):75. doi: 10.1186/s13000-018-0748-2.

12.

The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation.

Ouellet V, Aprikian A, Bergeron A, Brimo F, Bristow RG, Chevalier S, Drachenberg D, Fazli L, Fleshner NE, Gleave M, Karakiewicz P, Klotz L, Lacombe L, Lattouf JB, van der Kwast T, Squire JA, Latour M, Trudel D, Mes-Masson AM, Saad F.

BMC Urol. 2018 Sep 10;18(1):78. doi: 10.1186/s12894-018-0392-x.

13.

HtrA1 expression and the prognosis of high-grade serous ovarian carcinoma: a cohort study using digital analysis.

Gagné A, Têtu B, Orain M, Turcotte S, Plante M, Grégoire J, Renaud MC, Bairati I, Trudel D.

Diagn Pathol. 2018 Aug 21;13(1):57. doi: 10.1186/s13000-018-0736-6. Erratum in: Diagn Pathol. 2018 Sep 17;13(1):75.

14.

Optimization of the 2014 Gleason grade grouping in a Canadian cohort of patients with localized prostate cancer.

Wissing M, Brimo F, Chevalier S, Scarlata E, McKercher G, O'Flaherty A, Aprikian S, Thibodeau V, Saad F, Carmel M, Lacombe L, Têtu B, Ekindi-Ndongo N, Latour M, Trudel D, Aprikian A.

BJU Int. 2019 Apr;123(4):624-631. doi: 10.1111/bju.14512. Epub 2018 Sep 11.

PMID:
30113732
15.

A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray Cores.

Leyh-Bannurah SR, Trudel D, Latour M, Zaffuto E, Grosset AA, Tam C, Ouellet V, Graefen M, Budäus L, Aprikian AG, Lacombe L, Fleshner NE, Gleave ME, Mes-Masson AM, Saad F, Karakiewicz PI.

Pathol Oncol Res. 2019 Jul;25(3):979-986. doi: 10.1007/s12253-018-0408-6. Epub 2018 Apr 6.

PMID:
29623528
16.

The impact of intraductal carcinoma of the prostate on the site and timing of recurrence and cancer-specific survival.

Trinh VQ, Sirois J, Benzerdjeb N, Mansoori BK, Grosset AA, Albadine R, Latour M, Mes-Masson AM, Hovington H, Bergeron A, Ladouceur M, Fradet Y, Saad F, Trudel D.

Prostate. 2018 Jul;78(10):697-706. doi: 10.1002/pros.23513. Epub 2018 Mar 30.

PMID:
29603326
17.

Mesoscopic characterization of prostate cancer using Raman spectroscopy: potential for diagnostics and therapeutics.

Aubertin K, Trinh VQ, Jermyn M, Baksic P, Grosset AA, Desroches J, St-Arnaud K, Birlea M, Vladoiu MC, Latour M, Albadine R, Saad F, Leblond F, Trudel D.

BJU Int. 2018 Aug;122(2):326-336. doi: 10.1111/bju.14199. Epub 2018 Apr 13.

18.

A new method using Raman spectroscopy for in vivo targeted brain cancer tissue biopsy.

Desroches J, Jermyn M, Pinto M, Picot F, Tremblay MA, Obaid S, Marple E, Urmey K, Trudel D, Soulez G, Guiot MC, Wilson BC, Petrecca K, Leblond F.

Sci Rep. 2018 Jan 29;8(1):1792. doi: 10.1038/s41598-018-20233-3.

19.

Hematoxylin and Eosin Counterstaining Protocol for Immunohistochemistry Interpretation and Diagnosis.

Grosset AA, Loayza-Vega K, Adam-Granger É, Birlea M, Gilks B, Nguyen B, Soucy G, Tran-Thanh D, Albadine R, Trudel D.

Appl Immunohistochem Mol Morphol. 2019 Aug;27(7):558-563. doi: 10.1097/PAI.0000000000000626.

PMID:
29271792
20.

Development and characterization of a handheld hyperspectral Raman imaging probe system for molecular characterization of tissue on mesoscopic scales.

St-Arnaud K, Aubertin K, Strupler M, Madore WJ, Grosset AA, Petrecca K, Trudel D, Leblond F.

Med Phys. 2018 Jan;45(1):328-339. doi: 10.1002/mp.12657. Epub 2017 Nov 27.

PMID:
29106741

Supplemental Content

Loading ...
Support Center